PolyPeptide Group AG
Symbool: PPGN.SW
SIX
30.85
CHFMarktprijs vandaag
-20.2164
Koers/Winst Verhouding
-0.4777
Koers/Winst Groei Verhouding
1.02B
MRK Kapitalisatie
- 0.00%
DIV Rendement
PolyPeptide Group AG (PPGN-SW) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 279.04 | 101.1 | 49.1 | 67.8 | ||||||
balance-sheet.row.inventory | 564.08 | 128.5 | 145.1 | 113 | ||||||
balance-sheet.row.other-current-assets | 71.69 | 1.3 | 19.8 | 14.5 | ||||||
balance-sheet.row.total-current-assets | 1123.47 | 326.6 | 251.6 | 331.6 | ||||||
balance-sheet.row.property-plant-equipment-net | 1190.14 | 324.1 | 297.3 | 235.4 | ||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.long-term-investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.tax-assets | 42.61 | 16.7 | 8.3 | 10.3 | ||||||
balance-sheet.row.other-non-current-assets | -25.92 | 0 | -8.3 | -10.3 | ||||||
balance-sheet.row.total-non-current-assets | 1283.86 | 362.5 | 315.9 | 253.2 | ||||||
balance-sheet.row.other-assets | 25.92 | 0 | 8.3 | 10.3 | ||||||
balance-sheet.row.total-assets | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.account-payables | 160.69 | 60.9 | 45.9 | 28.5 | ||||||
balance-sheet.row.short-term-debt | 111.1 | 45.7 | 3.6 | 3.1 | ||||||
balance-sheet.row.tax-payables | 17.52 | 9.3 | 4.9 | 7.6 | ||||||
balance-sheet.row.long-term-debt-total | 97 | 68 | 9.4 | 10.3 | ||||||
Deferred Revenue Non Current | 47.26 | 23.2 | 7.5 | 9.2 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 8.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 237.3 | 1.4 | 50.1 | 75.5 | ||||||
balance-sheet.row.total-non-current-liabilities | 160.46 | 131.4 | 9.4 | 10.3 | ||||||
balance-sheet.row.other-liabilities | 146.11 | 0 | 48.6 | 59.6 | ||||||
balance-sheet.row.capital-lease-obligations | 87.25 | 23.3 | 21.2 | 18 | ||||||
balance-sheet.row.total-liab | 818.72 | 307.9 | 154.1 | 173.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 1.21 | 0.3 | 0.3 | 0.3 | ||||||
balance-sheet.row.retained-earnings | 775.36 | 165.1 | 214.1 | 196 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 74.69 | 23 | 17.7 | 13.2 | ||||||
balance-sheet.row.other-total-stockholders-equity | 763.27 | 192.7 | 189.5 | 211.6 | ||||||
balance-sheet.row.total-stockholders-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 2433.25 | - | - | - | ||||||
Total Investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.total-debt | 232.77 | 113.7 | 21.2 | 18 | ||||||
balance-sheet.row.net-debt | 24.11 | 18 | -16.3 | -118.3 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.47 | 30.5 | 24 | 18.7 | ||||||
cash-flows.row.deferred-income-tax | 46.42 | 3.1 | 13.2 | 28.7 | ||||||
cash-flows.row.stock-based-compensation | 2.05 | 0.8 | 1.2 | 1.2 | ||||||
cash-flows.row.change-in-working-capital | -29.34 | 46.2 | -14.3 | -29.9 | ||||||
cash-flows.row.account-receivables | -10.56 | 0 | 18.8 | -12.2 | ||||||
cash-flows.row.inventory | -17.62 | 15.5 | -33.1 | -17.7 | ||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-working-capital | -1.16 | 30.7 | 0 | 0 | ||||||
cash-flows.row.other-non-cash-items | 63.45 | 7.3 | -26.3 | -8.6 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 41.95 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | -9.95 | -2.8 | -3.3 | -6.9 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -137.95 | -59.5 | -78.4 | -80.8 | ||||||
cash-flows.row.debt-repayment | -3.51 | -55.2 | -3.3 | -41.4 | ||||||
cash-flows.row.common-stock-issued | 13.79 | 0 | 17.2 | 182.1 | ||||||
cash-flows.row.common-stock-repurchased | -13.93 | 0 | -13.9 | -5.5 | ||||||
cash-flows.row.dividends-paid | -9.67 | 0 | -9.7 | -135.3 | ||||||
cash-flows.row.other-financing-activites | 71.01 | 139.7 | -17.2 | 130.9 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 57.68 | 84.5 | -26.9 | 130.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | -2.27 | -3.3 | 1.1 | 11.7 | ||||||
cash-flows.row.net-change-in-cash | -40.6 | 58.2 | -98.8 | 119.1 | ||||||
cash-flows.row.cash-at-end-of-period | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 249.25 | 37.5 | 136.3 | 17.2 | ||||||
cash-flows.row.operating-cash-flow | 41.95 | 36.5 | 5.5 | 57.4 | ||||||
cash-flows.row.capital-expenditure | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.free-cash-flow | -86.05 | -20.2 | -69.6 | -16.6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 601.35 | 320.4 | 281 | 282.1 | ||||||
income-statement-row.row.cost-of-revenue | 544.59 | 315.7 | 229 | 182.4 | ||||||
income-statement-row.row.gross-profit | 56.76 | 4.6 | 52 | 99.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 2.71 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 70.54 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.operating-expenses | 99.79 | 41.1 | 42.3 | 37 | ||||||
income-statement-row.row.cost-and-expenses | 644.37 | 356.8 | 271.3 | 219.5 | ||||||
income-statement-row.row.interest-income | 8.77 | 0.1 | 2.1 | 2.8 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.total-operating-expenses | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.depreciation-and-amortization | 42.05 | 30.5 | 20.5 | 16.1 | ||||||
income-statement-row.row.ebitda-caps | 20.74 | - | - | - | ||||||
income-statement-row.row.operating-income | -21.3 | -36.5 | 12.5 | 67.4 | ||||||
income-statement-row.row.income-before-tax | -50.68 | -58.2 | 7.6 | 59.8 | ||||||
income-statement-row.row.income-tax-expense | 12.19 | -6.8 | 0.2 | 12.6 | ||||||
income-statement-row.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 |
Vaak gestelde vragen
Wat is PolyPeptide Group AG (PPGN.SW) totale activa?
PolyPeptide Group AG (PPGN.SW) totale activa is 689088000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 320372000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.015.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.161.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.106.
Wat is PolyPeptide Group AG (PPGN.SW) nettowinst (netto-inkomen)?
De nettowinst is -51440000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 113662000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 41110000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 95706000.000.